deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06914037

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies (COURAGE)

A Phase 1, Open-Label, Single-Arm Study of the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Sponsor: Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

Conditions Cutaneous T-cell Lymphoma (CTCL) NHL (Non-Hodgkin Lymphoma) Peripheral T-cell Lymphoma
Interventions CHT101
Updated 1 time since 2025 Last updated: Mar 30, 2025 Started: Mar 31, 2025 Primary completion: Mar 31, 2028 Completion: Mar 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cutaneous T-cell Lymphoma (CTCL) and NHL (Non-Hodgkin Lymphoma) and is currently actively recruiting participants. Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2025 – present · 14 months · monthly snapshotRecruiting

Change History

1 version recorded
Recruiting — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
  • Tianjin Medical University Cancer Institute and Hospital
Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations